Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Irene M Lagoja & Piet Herdewijn. (2007) Use of RNA in drug design. Expert Opinion on Drug Discovery 2:6, pages 889-903.
Read now
Read now
Ross A Kinloch & Peter J Cox. (2005) New targets for neuropathic pain therapeutics. Expert Opinion on Therapeutic Targets 9:4, pages 685-698.
Read now
Read now
Articles from other publishers (17)
Md. Karim, Kyi Tha, Iekhsan Othman, Mohammad Borhan Uddin & Ezharul Chowdhury. (2018) Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics 10:2, pages 65.
Crossref
Crossref
Indu Pal Kaur & Gaurav Sharma. (2012) siRNA. BioDrugs 26:6, pages 401-412.
Crossref
Crossref
Giorgia D. Ugarte, Tatiana Opazo, Francisco Leisewitz, Brigitte van Zundert & Martin Montecino. (2012) Runx1 and C/EBPβ transcription factors directly up-regulate P2X3 gene transcription. Journal of Cellular Physiology 227:4, pages 1645-1652.
Crossref
Crossref
Sarah M. Sweitzer, Cristina E. Minella, Steven P. Wilson & Srinivasa N. Raja. (2012) Peripheral opioid analgesia for the treatment of neuropathic pain: Gene mutation to virus mediated gene transfer. European Journal of Pain Supplements 4:S4, pages 251-256.
Crossref
Crossref
Philippe Sarret, Louis Doré-Savard, Pascal Tétreault, Valérie Bégin-Lavallée & Nicolas Beaudet. 2010. RNA Technologies and Their Applications. RNA Technologies and Their Applications
161
190
.
Thomas Christoph, Gregor Bahrenberg, Jean De Vry, Werner Englberger, Volker A. Erdmann, Moritz Frech, Babette Kögel, Thomas Röhl, Klaus Schiene, Wolfgang Schröder, Jost Seibler & Jens Kurreck. (2008) Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Molecular and Cellular Neuroscience 37:3, pages 579-589.
Crossref
Crossref
Xinjie LuDong LuMike ScullyVijay Kakkar. (2008) The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy. Perspectives in Medicinal Chemistry 2, pages 1177391X0800200.
Crossref
Crossref
Pedro Gonzalez-Alegre. (2007) Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacology & Therapeutics 114:1, pages 34-55.
Crossref
Crossref
Thais Federici & Nicholas M. Boulis. (2007) RIBONUCLEIC ACID INTERFERENCE FOR NEUROLOGICAL DISORDERS. Neurosurgery 60:1, pages 3-16.
Crossref
Crossref
Thomas Christoph, Arnold Grünweller, Joanna Mika, Martin K.-H. Schäfer, Erik J. Wade, Eberhard Weihe, Volker A. Erdmann, Robert Frank, Clemens Gillen & Jens Kurreck. (2006) Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochemical and Biophysical Research Communications 350:1, pages 238-243.
Crossref
Crossref
Thomas Röhl & Jens Kurreck. (2006) RNA interference in pain research. Journal of Neurochemistry 99:2, pages 371-380.
Crossref
Crossref
Mary J. Eaton. (2006) Cell and Molecular Approaches to the Attenuation of Pain after Spinal Cord Injury. Journal of Neurotrauma 23:3-4, pages 549-559.
Crossref
Crossref
J Weiler, J Hunziker & J Hall. (2005) Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Therapy 13:6, pages 496-502.
Crossref
Crossref
David J Snodin & Peter R Ryle. (2006) Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals. BioDrugs 20:1, pages 25-52.
Crossref
Crossref
Patrick Y. Lu, Frank Xie & Martin C. Woodle. 2005. Non-Viral Vectors for Gene Therapy, Second Edition: Part 2. Non-Viral Vectors for Gene Therapy, Second Edition: Part 2
115
142
.
Jack R. Bennink & Tara N. Palmore. (2004) The promise of siRNAs for the treatment of influenza. Trends in Molecular Medicine 10:12, pages 571-574.
Crossref
Crossref
Jonathan Hall. (2004) Unravelling the general properties of siRNAs: strength in numbers and lessons from the past. Nature Reviews Genetics 5:7, pages 552-557.
Crossref
Crossref